Background Inherited metabolic disorders associated with nephrocalcinosis are rare conditions. The aim of this study was to identify the genetic cause of an Israeli-Arab boy from a consanguineous family with severe nephrocalcinosis and kidney insufficiency. Methods Clinical and biochemical data of the proband and family members were obtained from both previous and recent medical charts. Genomic DNA was isolated from peripheral blood cells. The coding sequence and splice sites of candidate genes (CYP24A1, CYP27B1, FGF23, KLOTHO, SLC34A3 and SLC34A1) were sequenced directly. Functional studies were performed in Xenopus laevis oocytes and in transfected opossum kidney (OK) cells. Results Our patient was identified as having nephrocalcinosis in utero, and at the age of 16.5 years, he had kidney insufficiency but no bone disease. Genetic analysis revealed a novel homozygous missense mutation, Arg215Gln, in SLC34A1, which encodes the renal sodium phosphate cotransporter NaPiIIa. Functional studies of the Arg215Gln mutant revealed reduced transport activity in Xenopus laevis oocytes and increased intracellular cytoplasmic accumulation in OK cells.
Introduction
Nephrocalcinosis, defined as renal parenchyma calcification, is caused by a number of conditions that involve the dysregulation of calcium homeostasis and may lead to acute or chronic kidney injury [1] .
Inherited metabolic disorders associated with nephrocalcinosis with or without nephrolithiasis are rare conditions, the most studied are Dent disease, Bartter syndrome, familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) and renal hyperoxaluria (PH). More recently, loss-of-function mutations of the CYP24A1 gene, encoding for the Vitamin D-24-hydroxylase, were discovered to be a main cause of severe infantile hypercalcemia, hypercalciuria and nephrocalcinosis [2, 3] .
NaPiIIa is a member of the SLC34 family of sodium-driven phosphate co-transporters, mainly expressed in the apical brush border membrane of the kidney proximal tubule [4] . Extensive studies in murine models have shown that either complete deletion of the SLC34A1 gene or homozygosity loss-of-function NaPiIIa mutations reduced the renal reabsorption of phosphate, altered phosphate homeostasis, and led to renal calcification [5, 6] .
However, until recently the clinical effects of NaPiIIa mutations in humans were controversial. It has remained unclear whether human heterozygous mutations might be the cause of kidney stones [7, 8] . The clinical findings in the first reported homozygous NaPiIIa mutation in humans included Fanconi syndrome and bone disease without hypercalciuria or nephrocalcinosis [9] , whereas another paper described hypercalcemia and nephrocalcinosis without skeletal dysfunction [10] . Recent publications strengthen the involvement of SLC34A1 in hypercalcemia and kidney stones. A genomewide association study among 5,419 kidney stone cases found an association with a rare missense variant in SLC34A1 [11] . Halbritter et al. reported that out of 272 kidney stone patients screened for mutations in 30 genes suspected to be associated with kidney stones, 1 patient was found to have compound heterozygous mutations in SLC34A1 [12] . Finally, Schlingmann et al. reported causative mutations in SLC34A1 in cases of idiopathic infantile hypercalcemia [13] .
We studied an Israeli-Arab adolescent from a consanguineous family with severe nephrocalcinosis and kidney failure, and, using the candidate gene approach, identified a homozygous NaPiIIa missense mutation, p.Arg215Gln, as underlying the disease. The proband's mutation is described by Schlingmann et al. ([13] , supplementary material), but functional analysis was not performed. Here, we show that the potential pathogenic effect of this mutation is suggested by in silico analysis and is verified by functional studies in Xenopus laevis oocytes and in opossum kidney (OK) cells.
Subjects and methods

Subjects
We studied an Israeli-Arab adolescent boy with nephrocalcinosis and kidney insufficiency, and several members of his extended family. Clinical data were obtained both from previous medical charts and from recent evaluation.
Methods
Candidate gene sequencing
The history of hypocalcemia and nephrocalcinosis along with increased 1,25 dihydroxyvitamin D 3 and suppressed parathyroid hormone (PTH) levels prompted us to evaluate genes associated with calcium and phosphate homeostasis.
Genomic DNA was isolated from peripheral blood cells, applying the ArchivePure DNA Blood Kit (5 PRIME, Gaithersburg, MD, USA) according to the manufacturer's instructions. The coding sequence and splice sites of CYP24A1, CYP27B1, FGF23, KLOTHO, SLC34A3, and SLC34A1 were amplified by polymerase chain reaction (PCR) using intronic primers. Primers for CYP24A1 were described previously [3] . Sequences of the other primers will be provided on demand.
All PCR products were sequenced directly (ABI Prism 3100; Applied Biosystems, Foster City, CA, USA).
RT-PCR analysis
The RNA was extracted from peripheral blood using TRI Reagent® (Sigma-Aldrich, Saint Louise, MO, USA) according to the manufacturer's instructions. cDNA was generated using Verso™ cDNA Synthesis Kit (ABgene®, Thermo Scientific, UK) according to the manufacturer's instructions. A cDNA segment from exons 5 to 8 of SLC34A1 was amplified by PCR (forward primer: 5'-GTC AGC ATG GTC TCC TCT G -3', reverse primer: 5'-GGC ACC AGA TCT GGA TGA G-3'). PCR products were analyzed by electrophoresis in 2 % agarose gel.
Preparation of plasmid constructs
Full-length hSLC34A1 subcloned either into the KSM oocyte expression vector or into pEGFP-C1 (Clontech) [14] was used as a template to generate the p.Arg215Gln mutant, as described for other mutations [13] .
Cell culture and transient transfections
Opossum kidney cells (clone 3B/2) were cultured and transfected as described [13, 15] with either wild-type (WT) hNaPiIIa fused to the pEGFP-C1 vector or with the p.Arg215Gln. We performed two independent experiments, each in duplicate or triplicate.
Actin staining and confocal microscopy of OK cells
Upon expression of clear patches of WT hNaPiIIa signal (2-3 days after transfection), cells were fixed with paraformaldehyde, permeabilized with saponin, and stained with Texas Red®-X phalloidin (Invitrogen) (1:500) and mounted as described previously [16] . The subcellular final locations of the transfected cotransporters were analyzed by confocal laser scanning microscopy (Leica SP2) using a 63x oil immersion objective at the Center for Microscopy and Image Analysis, University of Zurich.
Expression of hNaPiIIa and the p.Arg215Gln mutant in Xenopus laevis oocytes Preparation of oocytes and the synthesis and injection of cRNA were performed as described [13] . All animal procedures were conducted in accordance with the Swiss Cantonal and Federal legislation relating to animal experimentation.
Experiments were performed 3 days after injection with non-injected control oocytes (NI) or oocytes expressing hNaPiIIa WT and the p.Arg215Gln mutant (6-10 oocytes/ group). 32 P i flux experiments were conducted according to established protocols [13] .
All voltage clamp experiments were performed using a two-electrode voltage clamp (TEC-10CX; NPI, Tamm, Germany). Oocytes were impaled with microelectrodes filled with 3 M KCl, with a typical resistance of <1 MΩ. The temperature of the recording chamber and incoming superfusate were regulated using Peltier cooling elements driven by a continuous feedback controller (TC-10; NPI). Data acquisition was performed using a 1440 Digidata (Molecular Devices, Sunnyvale, CA, USA). For recordings at constant holding potential, currents were acquired at >20 samples/s and filtered at 10 Hz. Faster sampling rates (up to 20 ksamples/s) were used for voltage step recordings with filtering (digital and analog) adjusted accordingly.
Steady-state currents were obtained using a protocol in which membrane voltage steps were made from the holding potential (Vh) = −60 mV, to test voltages in the range −140 to +40 mV, in 20-mV increments. The steady-state Pi-dependent current (IPi) was obtained by subtracting control traces (in 100Na solution) from the corresponding traces in the presence of Pi. Data were rejected if contaminated by endogenous Cl − currents. Experiments were performed with 0.1 and 1 mM in the presence of 100 mM Na or in a solution where 50 mM NaCl had been replaced by 50 mM LiCl.
Results
Clinical characteristics of the patient and family
An adolescent, now 18 years old, was first referred to our clinic at the age of 12 for evaluation of congenital nephrocalcinosis. He is the first child of healthy consanguineous parents of Israeli-Arab origin ( Fig. 1a ) with other three healthy siblings. A paternal aunt and grandmother and a maternal uncle were previously diagnosed with nephrolithiasis; the aunt had undergone extracorporeal lithotripsy. No cases of end-stage renal failure in the family were reported.
The patient was born at term in another hospital. Medullary nephrocalcinosis was suspected on fetal ultrasound and confirmed on neonatal and later repeated ultrasound examinations.
The child developed normally and was asymptomatic, but nephrocalcinosis persisted on repeated ultrasound examinations with normal-sized kidneys growing along the 30-50th percentile for age. However, on the most recent imaging a left kidney lower pole stone was found, along with cortical thinning and prominent diffuse medullary calcifications (Fig. 1b) .
Physical examination during the follow-up was normal, with growth and blood pressure within the normal range for age. Up to the age of 18 years, the patient did not show any sign of rickets or any other bone disease.
Laboratory investigations at the age of 16.5 years revealed normal serum calcium and phosphorus levels, slightly depressed PTH levels: 12.3-16.5 ng/L (normal 15-65 ng/L) and elevated 1,25 dihydroxyvitamin D: 166-230 pmol/L (normal 39-160 pmol/L) with normal 25 hydroxyvitamin D levels. Urinary calcium/creatinine was within low to normal range: 0.05-0.1 mg/mg in repeated 24-h urine collections. No phosphaturia was found, with TRP (tubular reabsorption of phosphate) values of 92-96.7 % on repeat samples and TmP/GFR (tubular maximum reabsorption of phosphate to glomerular filtration rate) of 2.9-4.02 mg/dl. Citrate excretion was slightly depressed with normalization after lemon juice supplement. Urinary oxalate, uric acid, and cystine excretion were also normal. Normal urinary lysozyme concentration was found and a normal albumin/creatinine ratio.
Unfortunately, we could not retrieve detailed data on the relevant laboratory parameters before the referral to our clinic, especially for the neonatal period when, according to the parents and the family physician, he was hospitalized because of hypercalcemia and nephrocalcinosis was already present. The only relevant findings were serum calcium of 12.4 mg/dl and phosphorus 3.2 mg/dl at the age of 5 months (normal range for age: calcium 8.8-10.8 mg/dl, phosphorus 3.8-6.5 mg/dl), and hypercalciuria at the ages of 6-10 years found in urine samples in the range of 0.25-0.35 mg/mg calcium/creatinine (normal range for age: < 0.2).
Kidney function deteriorated over time: GFR estimated by creatinine clearance was 91 at the age of 12 years, 77 at the age of 14 years, and was then 60 at the age of 18 years. Tc-99 m Dimercaptosuccinic acid (DMSA) scan at the age of 15 showed two kidneys of similar size and function and no uptake defects. Ultrasound of the kidney performed at the age of 17 showed normal sized kidneys with medullary calcifications.
We also evaluated nine family members, including the three subjects with a history of nephrolithiasis. All of them had normal kidney function, normal serum calcium and phosphorus values, and normal calcium/creatinine and phosphorus/creatinine ratios in urine (data not shown).
Genetic analysis of candidate genes
We first examined several genes that are known to be involved in the regulation of calcium and vitamin D handling and have been linked to nephrocalcinosis or kidney stones. We sequenced the genes CYP24A1, CYP27B1, KLOTHO, and FGF23 and found no mutation. We then sequenced SLC34A1 and SLC34A3, the genes coding for the renal phosphate renal transporters NaPiIIa and NaPiIIc. In SLC34A3, in which mutations are known to cause hypophosphatemic rickets with hypercalciuria and hyperphosphaturia, we identified a heterozygous insertion-c.967_968insAGCTCCTGGCCG-that was also present in the healthy father (data not shown).
In SLC34A1 we identified a novel homozygous missense mutation, p.Arg215Gln (Fig. 1c) . Several family members, with or without a history of nephrolithiasis, were found to be heterozygous carriers of this mutation. However, in the proband's grandmother, who reported having had kidney stones in the past, no mutation was found (Fig. 1a) .
In silico studies
The new mutation detected in the SLC34A1 gene (hg19:chr5:176814874) was examined in various large data sets to exclude it from being a polymorphism. A variant in this position was not evident in the 1,000 genomes project [17] or in the ESP (ESP http://evs.gs.washington.edu/EVS/) project (zero alleles). In addition, a variant in this position does not appear in the ExAC browser, which aggregates information on more than 60,000 individuals (Exome Aggregation Consortium-ExAC, Cambridge, MA, USA, http://exac. broadinstitute.org) either. Finally, we examined 100 normal Israeli-Arab genomes, and did not find even a single mutated allele. Furthermore, the mutation we describe replaces an amino acid highly conserved among the members of the SLC34 family (Fig. 2a) .
The mutation is located in the last nucleotide of the sixth exon. As such, it may affect the splicing donor motif. cDNA analysis of the proband and his father showed that this is not the case (Fig. 1d) .
No experimental structure has been solved for this protein; thus, a careful structural insight regarding this mutation is missing. No structure for a close homolog is available; thus, it is also difficult to construct a confident model. However, Fenollar-Ferrer et al. [18] constructed a model based on the structure of the Vibrio cholerae Na + dicarboxylate transporter, which shares overall sequence identity of around 15 % with human SLC34A1. They suggest inverted structural repeats in the overall topology, as is often found in other families of transporters. The model suggests that the mutation is located in the first structural repeat unit, in the N-terminal domain, in or close to the cytoplasmic side of the membrane (Fig. 2b) .
Functional studies
Transport activity of mutant NaPiIIa
Expression of human WT NaPiIIa in Xenopus laevis oocytes induced sodium-dependent phosphate uptake, whereas oocytes not injected with cRNA showed only negligible phosphate uptake. Moreover, the p.Arg215Gln NaPiIIa transporter mediated some phosphate transport, significantly more than in non-injected oocytes, but also significantly less than in WTexpressing oocytes (Figure 3a) .
Electrophysiological characterization of mutant NaPiIIa
We assessed the electrogenic behavior of the p.Arg215Gln mutant by functional expression in Xenopus oocytes using the standard two-electrode voltage clamp (TEVC) technique. We used our standard screening assay [19] to compare the normalized response to 0.1 mM Pi (in 100Na); 50 mM Na (1 mM Pi) and 50 mM Na + 50 MM Li (1 mM Pi; Fig 3b) . Compared with the WT hNaPiIIa (Fig. 3b, left panel) , the mutant showed a more curvilinear I-V in response to 1 mM Pi, suggesting that the removal of charge at 215 had affected the voltage dependence (Fig 3b, right panel) . The response to 0.1 mM Pi (100Na + 0.1Pi) was suppressed compared with the WT suggesting that the mutagenesis had marginally compromised the apparent affinity for P i (K 0.5 Pi ). Based on this twostate assay, we predict that this would amount to an approximately two-fold increase in K 0.5
Pi (see supplementary figure, Fenollar-Ferrer et al. [19] ). Moreover, whereas for the WT, the normalized responses to a 50 % reduction in external Na + (50Na + 1Pi) or replacement of 50 % external Na + ions with Li + ions (50Na50Li + 1Pi) were similar, p.Arg215Gln showed a slightly increased response with regard to the Li + substitution.
Expression in renal proximal tubule cells
Wild type NaPiIIa tagged with EGFP was transiently transfected into the renal OK cell line, a model for the proximal tubule. Wild-type NaPiIIa localized to the luminal brush border membrane as indicated by the yellow color resulting from colocalization with actin (stained in red) expressed in apical microvilli (Fig. 3c, left panel) . Lateral views of the same cell indicate that a substantial part of NaPiIIa is found in the apical membrane, as suggested by only faint green intracellular staining. The p.Arg215Gln mutant also localized in part to the brush border membrane and colocalized there with actin (yellow overlay). However, in contrast to the WT situation, distinct intracellular green staining was observed, suggesting partial retention of the mutant protein (Fig. 3c, right panel) .
Discussion
We report that a homozygous missense mutation in the sodium-phosphate co-transporter NaPiIIa, p.Arg215Gln, is the likely cause of nephrocalcinosis and kidney insufficiency. The causative role of this mutation in the pathogenesis of our patient's kidney disease is supported by the following findings: Fig. 2 Analysis of the conservation and structural context of the R215 residue. a R215 is located at a conserved site within a conserved domain. b The predicted location of R215 residue according to the Fenollar-Ferrer model is shown [18, 19] . c Secondary structure and accessibility predictions for SLC34A1. The mutation is predicted to fall on the border between membrane helix and cytoplasmic loop and on the border between a buried part of the protein and an exposed part 1. Among the 9 family members studied, only the homozygous proband had nephrocalcinosis and kidney insufficiency. 2. The nucleotide variant that we identified was not found in the general population, and was absent from 200 alleles of healthy unrelated Israeli-Arab individuals.
3. The mutated amino acid, the arginine in position 215, is highly conserved through evolution and in the SLC34 family of phosphate transporters (Fig. 2a ). 4. In silico studies suggest that this mutation might result in a significant change in both the size and the charge in this position, and is deleterious to the protein. Fig. 3 a Phosphate transport activity of WT and mutant p.Arg215Gln hNaPiIIa. 32 Phosphate uptakes were performed in Xenopus oocytes 3 days after injection of cRNA encoding hNaPiIIa. Data from two independent batches of oocytes, each consisting of 8-10 oocytes. All data were normalized to the transport activity of WT hNaPiIIa. b Normalized electrogenic behavior of oocytes expressing the human NaPiIIa WT and mutant p.Arg215Gln. Data were normalized to the response when superfusing with 100Na + 1Pi at −100 mV. Data from WT were modified and redrawn according to Fenollar-Ferrer et al. [19] .
Each data point for p.Arg215Gln is mean ± SEM (standard error of the mean) of 4-5 cells. c Expression of EGFP-tagged human NaPiIIa cotransporter in renal opossum kidney (OK) cells. Cells were transiently transfected with pEGFP plasmids containing either human WT or mutant hNaPiIIa, and with the empty pEGFP plasmid. Confluent cultures were viewed on a confocal microscope. Top panels: focal planes of apical projections. Bottom panels: cross sections. NaPiIIa signal is shown in green and actin staining in red. Yellow indicates colocalization of NaPiIIa and actin in apical microvilli. NI non-injected, WT wild-type 5. The results of in vitro expression studies indicate that the single amino acid change found in our patient suffices to reduce phosphate transport.
Our findings are in agreement with those found in animal models of reduced or absent NaPiIIa function. In mice, a homozygous single amino acid substitution in NaPiIIa altered phosphate (Pi) homeostasis and led to renal calcification [5] . NaPiIIa knock-out mice show increased urinary Pi excretion, hypophosphatemia, elevated serum 1,25 dihydroxyvitamin D levels, decreased serum PTH levels, hypercalcemia, and hypercalciuria [6] .
In humans, however, the impact of heterozygous NaPiIIa mutations in the formation of kidney stones is controversial and the clinical effects of homozygous mutations vary. The first study on the role of NaPiIIa in human kidney disease and bone demineralization was published by Prie et al. in 2002 [7] . In that report, 2 out of 20 patients with urolithiasis, bone deformation, and hypophosphatemia were found to be heterozygous carriers of NaPiIIa missense mutations (A48F; V147M). Functional analysis in Xenopus laevis oocytes demonstrated altered function and dominant negative effects of the mutated transporter. These findings were later challenged by two other studies: Virkki et al. examined the function of the same two mutations and found similar apical expression of mutated and WT proteins in OK cells. Furthermore, oocyte studies excluded a dominant negative effect of both mutations [14] . Lapointe et al. examined several NaPiIIa variants found in a cohort of 98 pedigrees with a history of multiple calcium kidney stones, including non-synonymous mutations and a truncation deletion. No difference was found between WT and heterozygous carriers in terms of calcium and phosphorus excretion; thus, the authors concluded that the variants described had no clinical significance [8] .
Interestingly, several reports have described either hypophosphatemia [20] or infantile hypercalcemia and nephrocalcinosis [21] in patients with Sotos syndrome, caused by a heterozygous microdeletion on chromosome 5q35, which removes both the NSD1 and the SLC34A1 genes. Sotos syndrome is characterized by bone overgrowth and mental retardation due to haploinsufficiency of the NSD1 gene. The calcium and phosphorus disorders were assumed to be the consequence of NaPiIIa haploinsufficiency, but it is not clear whether other changes due to the deletion also contribute to the phenotype.
The first report of a homozygous SLC34A1 mutation in a human described two Israeli-Arab siblings with hypophosphatemic rickets, hypercalciuria, highly elevated 1, 25 dihydroxyvitamin D levels, and partial Fanconi syndrome. Both carried an in-frame duplication of 21 bp that was shown in Xenopus laevis oocytes and OK cells to prevent transport of the protein to the cell membrane, thereby leading to complete loss of function of the transporter [9] . The occurrence of Fanconi syndrome in the context of a SLC34A1 mutation is not clear. In two different mouse models of SLC34A1 deficiency due to genetic deletion or compound heterozygous mutations no signs of Fanconi syndrome have been observed [22] . Suggested explanations include a specific toxic tubular effect of this particular mutation due to intracellular accumulation or an additional mutation in this consanguineous family [23] .
Rajagopal et al. reported another mutation in SLC34A1, p.Arg495His, in two siblings who presented with hypercalciuria and nephrocalcinosis [10] . Interestingly, according to our model, the p.Arg495His mutation was predicted to fall within a similar context to our mutation, within a cytoplasmic loop. This mutation is located in a lower quality region of our model; thus, we cannot verify or contradict their conclusion.
Screening a cohort of patients with kidney stones, Halbritter et al. identified one patient compound heterozygous for the p.Val91_Ala97del and p.Arg512Cys mutations [12] . There is no information available on the functional consequences of the p.Arg512Cys mutation. Of note, the p.Val91_Ala97del had been identified previously by Lapointe et al. [8] , and was suggested to be nonpathogenic. However, Schlingmann et al. reported no transport defect, but showed a slight but clearly visible trafficking defect [13] .
Most recently, Schlingmann et al. [13] reported on 16 cases of infantile idiopathic hypercalcemia with causative autosomal recessive mutations in SLC34A1. Functional studies of some of the mutations demonstrated disturbed trafficking to the plasma membrane and loss of phosphate transport activity. The mutation that we evaluated, p.Arg215Gln, is predicted to be harmful to the protein by most predictive tools. As the mutation affects a charged residue and may be located in a predicted transmembrane domain, it could be expected to alter helical packing and/or mobility of the transporter in the membrane. Our in vitro results indeed suggest reduced transport function of the p.Arg215Gln mutation in the oocyte assay and impaired trafficking of the mutant protein to the plasma membrane in OK cells. The p.Arg215Gln caused only partial reduction in phosphate transport, as opposed to the loss of phosphate transport shown by Schlingmann et al. [13] .
The results of electrophysiological characterization suggest that the Arg → Gln substitution at position 215 does indeed alter the voltage-dependent kinetics and the interaction of cations with the transporter. This in turn would lead to the observed reduced apparent affinity for P i . Given that under physiological conditions, the renal P i at pH 7.4 is far in excess of K 0.5 Pi , we would conclude that the mutation had marginal effects on the transport behavior. However, we cannot exclude the possibility of a somewhat compromised contribution of NaPiIIa to overall proximal tubular Pi influx at low P i below or close to the reported WT K 0. 5 Pi for human NaPiIIa of ∼100 μM. The reduced apical expression may account for most of the observed phenotypes in vivo, reducing the overall capacity of the kidney to conserve phosphate.
Based on animal data, mutations in SLC34A1 leading to complete loss of function or gene deletion would be expected to cause renal phosphate loss. However, the mutation described here may exert only a mild impairment of renal phosphate reabsorption. Moreover, the increase in 1,25 dihydroxyvitamin D may fully compensate for the defect in NaPiIIa by upregulating NaPiIIc, at the expense of increased intestinal calcium absorption and subsequent renal hypercalciuria, facilitating nephrocalcinosis.
Unlike the phenotype in humans with mutation of the second kidney phosphate transporter, NaPiIIc (SLC34A3), hypophosphatemic rickets is not a frequent feature in patients with SLC34A1 mutations. Whether heterozygous NaPiIIa mutations can cause kidney stones remains to be proven. Our family included 6 heterozygous carriers of the mutation, only 2 of which had a history of kidney stones. The proband's grandmother reported kidney stones, although she carried two WT SLC34A1 alleles. Thus, other hereditary or environmental factors contributed to the development of kidney stones in this family, and maybe also in previously reported heterozygous carriers of different SLC34A1 variants [7, 8] . Kidney stone formation against a background of heterozygous SLC34A1 mutations may provide an example of gene-environment interactions and remain to be deciphered in more detail.
Conclusion
We present severe nephrocalcinosis and renal insufficiency in a patient carrying a homozygous (p.Arg215Gln) mutation of the renal phosphate transporter NaPiIIa causing partial loss of function.
The prominent effect of this mutation is increased serum calcium and renal calcification, rather than complications of phosphate loss. Our interpretation for these findings is that the mutation described here may exert only a mild impairment of renal phosphate reabsorption, probably compensated for by the upregulation of NaPiIIc due to increased 1,25 dihydroxyvitamin D. The elevation of 1,25 dihydroxyvitamin D results in increased intestinal calcium absorption, which leads to the severe nephrocalcinosis seen in our patient. Thus, mutations in SLC34A1 increase the risk for hypercalciuria and nephrocalcinosis. We assume that eventually these mutations lead to renal insufficiency, as in the patient described here. Further followup studies of young patients with SLC34A1 mutations are needed to prove this.
